Vernakalant: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|A detailed overview of the antiarrhythmic medication Vernakalant}} | |||
== | ==Vernakalant== | ||
Vernakalant | [[File:Vernakalant.svg|thumb|right|Chemical structure of Vernakalant]] | ||
'''Vernakalant''' is a medication used in the management of [[atrial fibrillation]], a common type of irregular heartbeat. It is classified as a class III antiarrhythmic agent and works by blocking specific ion channels in the heart, which helps to restore normal heart rhythm. | |||
== | ==Mechanism of Action== | ||
Vernakalant | Vernakalant primarily affects the atrial tissue of the heart. It blocks multiple ion channels, including the [[sodium channel|sodium]] and [[potassium channel|potassium]] channels, which are crucial for the propagation of electrical signals in the heart. By inhibiting these channels, Vernakalant prolongs the refractory period and slows down the conduction of electrical impulses, thereby helping to terminate atrial fibrillation. | ||
== | ==Pharmacokinetics== | ||
Vernakalant is administered intravenously, allowing for rapid onset of action. It is metabolized in the liver and has a relatively short half-life, which makes it suitable for acute management of atrial fibrillation. The drug is excreted primarily through the kidneys. | |||
== | ==Clinical Use== | ||
Vernakalant | Vernakalant is indicated for the rapid conversion of recent-onset atrial fibrillation to sinus rhythm in adults. It is particularly effective in patients with atrial fibrillation of less than 7 days duration. The use of Vernakalant is contraindicated in patients with severe [[heart failure]], significant [[hypotension]], or recent [[myocardial infarction]]. | ||
== | ==Side Effects== | ||
Common side effects of Vernakalant include taste disturbances, sneezing, and nausea. More serious adverse effects can include hypotension and [[bradycardia]]. Due to its potential to cause serious cardiovascular events, Vernakalant should be administered under close medical supervision. | |||
== Related | ==Related pages== | ||
* [[Atrial fibrillation]] | * [[Atrial fibrillation]] | ||
* [[Antiarrhythmic agent]] | * [[Antiarrhythmic agent]] | ||
* [[Sodium channel]] | |||
* [[Potassium channel]] | * [[Potassium channel]] | ||
[[Category:Antiarrhythmic agents]] | [[Category:Antiarrhythmic agents]] | ||
[[Category:Cardiology]] | |||
Latest revision as of 03:37, 13 February 2025
A detailed overview of the antiarrhythmic medication Vernakalant
Vernakalant[edit]
Vernakalant is a medication used in the management of atrial fibrillation, a common type of irregular heartbeat. It is classified as a class III antiarrhythmic agent and works by blocking specific ion channels in the heart, which helps to restore normal heart rhythm.
Mechanism of Action[edit]
Vernakalant primarily affects the atrial tissue of the heart. It blocks multiple ion channels, including the sodium and potassium channels, which are crucial for the propagation of electrical signals in the heart. By inhibiting these channels, Vernakalant prolongs the refractory period and slows down the conduction of electrical impulses, thereby helping to terminate atrial fibrillation.
Pharmacokinetics[edit]
Vernakalant is administered intravenously, allowing for rapid onset of action. It is metabolized in the liver and has a relatively short half-life, which makes it suitable for acute management of atrial fibrillation. The drug is excreted primarily through the kidneys.
Clinical Use[edit]
Vernakalant is indicated for the rapid conversion of recent-onset atrial fibrillation to sinus rhythm in adults. It is particularly effective in patients with atrial fibrillation of less than 7 days duration. The use of Vernakalant is contraindicated in patients with severe heart failure, significant hypotension, or recent myocardial infarction.
Side Effects[edit]
Common side effects of Vernakalant include taste disturbances, sneezing, and nausea. More serious adverse effects can include hypotension and bradycardia. Due to its potential to cause serious cardiovascular events, Vernakalant should be administered under close medical supervision.
